Aura Biosciences is a startup based in the United States, most recent round Series-c-plus, 6 tracked investors.
Based in the United States, Aura Biosciences is a startup founded in 2018. Its most recent tracked round is Series-c-plus. Brouky records 6 investors associated with the company.
Aura Biosciences is a clinical-stage biotechnology company developing precision therapies for solid tumors with the goal of preserving organ function; its lead candidate belzupacap sarotalocan (bel-sar, AU-011) is in a global Phase 3 trial for early choroidal melanoma and is being evaluated in other ocular oncology indications and bladder cancer.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.